Avanzanite Bioscience
Cecilia Bröms-Thell is a highly experienced professional who currently holds various roles in different companies and organizations. Cecilia has a background in business and life sciences with a focus on innovation and strategic development. Cecilia has a strong track record in executive positions and board memberships, showcasing their leadership skills and expertise in the field. Their education includes studies at both Akademi Båstad and Karolinska Institutet.
This person is not in any teams
This person is not in any offices
Avanzanite Bioscience
Founded by biopharmaceutical executives, Adam Plich and Anant Murthy, Avanzanite is on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word ‘Tanzanite’ – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian. The economic goal is to offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets. This is the unique expertise and core competency of our team following decades of operating experience navigating this area. Equally important, our humanitarian goals stem from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live. Avanzanite Bioscience B.V. is a fully authorized distributor of medicinal products within the European Economic Area, Switzerland and the UK, with a Wholesale Distributor Authorization (WDA) issued by Farmatec in the Netherlands.